balversa Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Balversa, and when can generic versions of Balversa launch?
Balversa is a drug marketed by Janssen Biotech and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and ninety patent family members in forty-nine countries.
The generic ingredient in BALVERSA is erdafitinib. One supplier is listed for this compound. Additional details are available on the erdafitinib profile page.
DrugPatentWatch® Generic Entry Outlook for Balversa
Balversa was eligible for patent challenges on April 12, 2023.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 9, 2036. This may change due to patent challenges or generic licensing.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for balversa?
- What are the global sales for balversa?
- What is Average Wholesale Price for balversa?
Summary for balversa
International Patents: | 290 |
US Patents: | 8 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 52 |
Clinical Trials: | 8 |
Patent Applications: | 188 |
Drug Prices: | Drug price information for balversa |
What excipients (inactive ingredients) are in balversa? | balversa excipients list |
DailyMed Link: | balversa at DailyMed |


DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for balversa
Generic Entry Date for balversa*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for balversa
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Cancer Institute (NCI) | Phase 1 |
M.D. Anderson Cancer Center | Phase 2 |
Janssen Research & Development, LLC | Phase 2 |
Pharmacology for balversa
Paragraph IV (Patent) Challenges for BALVERSA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
BALVERSA | Tablets | erdafitinib | 3 mg, 4 mg and 5 mg | 212018 | 1 | 2023-04-12 |
US Patents and Regulatory Information for balversa
balversa is protected by seventeen US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of balversa is ⤷ Try for Free.
This potential generic entry date is based on patent ⤷ Try for Free.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | Y | Y | ⤷ Try for Free | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for balversa
When does loss-of-exclusivity occur for balversa?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 3645
Patent: USO DE UN DEPURADOR DE FORMALDEHÍDO EN UNA COMPOSICIÓN FARMACÉUTICA
Estimated Expiration: ⤷ Try for Free
Australia
Patent: 16218000
Patent: Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
Estimated Expiration: ⤷ Try for Free
Patent: 20250263
Patent: PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE
Estimated Expiration: ⤷ Try for Free
Patent: 22291429
Patent: PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE
Estimated Expiration: ⤷ Try for Free
Brazil
Patent: 2017017009
Patent: usos de um sequestrante de formaldeído e de uma composição farmacêutica, métodos para impedir, adiar, retardar ou diminuir a transformação de um composto e para tratar câncer, e, composição farmacêutica.
Estimated Expiration: ⤷ Try for Free
Canada
Patent: 76356
Patent: COMPOSITIONS PHARMACEUTIQUES COMPRENANT LA N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE)
Estimated Expiration: ⤷ Try for Free
Chile
Patent: 17002022
Patent: Composiciones farmaceuticas que contienen n-(3,5-dimetilfosfeno) - n'-(1-metiletil) - n - [3-(1-metil-1h-pirazol-4-yl) quinoxalina - 6 - yl] etano -1,2 - diamina
Estimated Expiration: ⤷ Try for Free
China
Patent: 7427511
Patent: 包含N‑(3,5‑二甲氧基苯基)‑N’‑(1‑甲基乙基)‑N‑[3‑(1‑甲基‑1H‑吡唑‑4‑基)喹喔啉‑6‑基]乙烷‑1,2‑二胺的药物组合物 (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE)
Estimated Expiration: ⤷ Try for Free
Patent: 8290184
Patent: 真空喷嘴 (Vacuum nozzle)
Estimated Expiration: ⤷ Try for Free
Patent: 3209102
Patent: 包含N-(3,5-二甲氧基苯基)-N’-(1-甲基乙基)-N-[3-(1-甲基-1H-吡唑-4-基)喹喔啉-6-基]乙烷-1,2-二胺的药物组合物 (Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine)
Estimated Expiration: ⤷ Try for Free
Colombia
Patent: 17008862
Patent: Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina
Estimated Expiration: ⤷ Try for Free
Costa Rica
Patent: 170411
Patent: COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN N-(3,5-DIMETOXIFENIL)-N-(1-METILETIL)-N-[3-(1-METIL-1H-PIRAZOL-4-IL-QUIN OXALIN-6-IL]ETANO-1,2-DIAMINA
Estimated Expiration: ⤷ Try for Free
Croatia
Patent: 0211244
Estimated Expiration: ⤷ Try for Free
Cyprus
Patent: 24432
Estimated Expiration: ⤷ Try for Free
Denmark
Patent: 56109
Estimated Expiration: ⤷ Try for Free
Eurasian Patent Organization
Patent: 9646
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ N-(3,5-ДИМЕТОКСИФЕНИЛ)-N'-(1-МЕТИЛЭТИЛ)-N-[3-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)ХИНОКСАЛИН-6-ИЛ]ЭТАН-1,2-ДИАМИН (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE)
Estimated Expiration: ⤷ Try for Free
Patent: 1791798
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ N-(3,5-ДИМЕТОКСИФЕНИЛ)-N'-(1-МЕТИЛЭТИЛ)-N-[3-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)ХИНОКСАЛИН-6-ИЛ]ЭТАН-1,2-ДИАМИН
Estimated Expiration: ⤷ Try for Free
European Patent Office
Patent: 56109
Patent: COMPOSITIONS PHARMACEUTIQUES COMPRENANT LA N-(3,5-DIMÉTHOXYPHÉNYL)-N'-(1-MÉTHYLÉTHYL)-N-[3-(1-MÉTHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ÉTHANE-1,2-DIAMINE (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE)
Estimated Expiration: ⤷ Try for Free
Patent: 47143
Patent: BUSE À VIDE (VACUUM NOZZLE)
Estimated Expiration: ⤷ Try for Free
Patent: 49954
Patent: COMPOSITIONS PHARMACEUTIQUES COMPRENANT N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE)
Estimated Expiration: ⤷ Try for Free
Hungary
Patent: 56761
Estimated Expiration: ⤷ Try for Free
Israel
Patent: 3700
Patent: תכשירים רוקחיים המכילים n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine (Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine)
Estimated Expiration: ⤷ Try for Free
Patent: 1024
Patent: תכשירים רוקחיים המכילים n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine (Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine)
Estimated Expiration: ⤷ Try for Free
Patent: 0469
Patent: תכשירים רוקחיים המכילים n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine (Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine)
Estimated Expiration: ⤷ Try for Free
Japan
Patent: 96588
Estimated Expiration: ⤷ Try for Free
Patent: 50831
Estimated Expiration: ⤷ Try for Free
Patent: 18505193
Patent: N−(3,5−ジメトキシフェニル)−N’−(1−メチルエチル)−N−[3−(1−メチル−1H−ピラゾール−4−イル)キノキサリン−6−イル]エタン−1,2−ジアミンを含んでなる医薬組成物
Estimated Expiration: ⤷ Try for Free
Patent: 21038241
Patent: N−(3,5−ジメトキシフェニル)−N’−(1−メチルエチル)−N−[3−(1−メチル−1H−ピラゾール−4−イル)キノキサリン−6−イル]エタン−1,2−ジアミンを含んでなる医薬組成物 (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE)
Estimated Expiration: ⤷ Try for Free
Patent: 23011758
Patent: N-(3,5-ジメトキシフェニル)-N’-(1-メチルエチル)-N-[3-(1-メチル-1H-ピラゾール-4-イル)キノキサリン-6-イル]エタン-1,2-ジアミンを含んでなる医薬組成物
Estimated Expiration: ⤷ Try for Free
Jordan
Patent: 0200201
Patent: تركيبات صيدلانية تشتمل على N-(3.5- ثنائي ميثوكسي فينيل)-N'-(1-ميثيل إيثيل)-N-[3-(ميثيل-1H-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE)
Estimated Expiration: ⤷ Try for Free
Patent: 95
Patent: تركيبات صيدلانية تشتمل على N- (3.5- ثنائي ميثوكسي فينيل)-N-(1-ميثيل إيثيل)-N- 3-( ميثيل-H1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين) (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE)
Estimated Expiration: ⤷ Try for Free
Lithuania
Patent: 56109
Estimated Expiration: ⤷ Try for Free
Malaysia
Patent: 6599
Patent: PHARMACEUTICAL COMPOSITONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE
Estimated Expiration: ⤷ Try for Free
Mexico
Patent: 17010287
Patent: COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN N-(3,5-DIMETOXIFENIL)-N '-(1-METILETIL)-N-[3-(1-METIL-1H-PIRAZOL-4-IL)QUINOXALIN-6-IL]ETA NO-1,2-DIAMINA. (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N' -(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL] ETHANE-1,2-DIAMINE.)
Estimated Expiration: ⤷ Try for Free
Patent: 21004110
Patent: COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN N-(3,5- DIMETOXIFENIL)-N'-(1-METILETIL)-N-[3-(1-METIL-1H- PIRAZOL-4-IL)QUINOXALIN-6-IL]ETANO-1,2-DIAMINA. (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N' -(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL] ETHANE-1,2-DIAMINE.)
Estimated Expiration: ⤷ Try for Free
Morocco
Patent: 496
Patent: COMPOSITIONS PHARMACEUTIQUES COMPRENANT LA N-(3,5-DIMÉTHOXYPHÉNYL)-N'-(1-MÉTHYLÉTHYL)-N-[3-(1-MÉTHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ÉTHANE-1,2-DIAMINE
Estimated Expiration: ⤷ Try for Free
Patent: 571
Patent: COMPOSITIONS PHARMACEUTIQUES COMPRENANT N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE
Estimated Expiration: ⤷ Try for Free
New Zealand
Patent: 4516
Estimated Expiration: ⤷ Try for Free
Nicaragua
Patent: 1700101
Patent: COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN N - (3, 5 - DIMETOXIFENIL) - N'- (1-METILETIL) - N - [3-(1-METIL-1H-PIRAZOL-4-IL) QUINOXALINA-6-IL]ETANO-1,2-DIAMINA
Estimated Expiration: ⤷ Try for Free
Philippines
Patent: 017501421
Patent: PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N`-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE
Estimated Expiration: ⤷ Try for Free
Poland
Patent: 56109
Estimated Expiration: ⤷ Try for Free
Portugal
Patent: 56109
Estimated Expiration: ⤷ Try for Free
San Marino
Patent: 02100450
Estimated Expiration: ⤷ Try for Free
Serbia
Patent: 221
Patent: FARMACEUTSKE KOMPOZICIJE KOJE SADRŽE N-(3,5-DIMETOKSIFENIL)-NꞋ-(1-METILETIL)-N-[3-(1-METIL-1H-PIRAZOL-4-IL)KVINOKSALIN-6-IL]ETAN-1,2-DIAMIN (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE)
Estimated Expiration: ⤷ Try for Free
Singapore
Patent: 202000734Y
Patent: PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE
Estimated Expiration: ⤷ Try for Free
Patent: 201706472R
Patent: PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE
Estimated Expiration: ⤷ Try for Free
Slovenia
Patent: 56109
Estimated Expiration: ⤷ Try for Free
South Korea
Patent: 2708049
Estimated Expiration: ⤷ Try for Free
Patent: 170110145
Patent: N--N'--N-[3-(1-메틸-1H-피라졸-4-일)퀴녹살린-6-일]에탄-1,2-디아민을 포함하는 제약 조성물
Estimated Expiration: ⤷ Try for Free
Patent: 240140190
Estimated Expiration: ⤷ Try for Free
Spain
Patent: 83829
Estimated Expiration: ⤷ Try for Free
Taiwan
Patent: 19960
Estimated Expiration: ⤷ Try for Free
Patent: 34020
Estimated Expiration: ⤷ Try for Free
Patent: 1630608
Patent: New compositions
Estimated Expiration: ⤷ Try for Free
Patent: 2123939
Patent: New compositions
Estimated Expiration: ⤷ Try for Free
Ukraine
Patent: 3767
Patent: ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ З ВМІСТОМ N-(3,5-ДИМЕТОКСИФЕНІЛ)-N'-(1-МЕТИЛЕТИЛ)-N-[3-(1-МЕТИЛ-1Н-ПІРАЗОЛ-4-ІЛ)ХІНОКСАЛІН-6-ІЛ]ЕТАН-1,2-ДІАМІНУ (PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE)
Estimated Expiration: ⤷ Try for Free
United Kingdom
Patent: 42142
Patent: Vacuum nozzle
Estimated Expiration: ⤷ Try for Free
Patent: 1515912
Estimated Expiration: ⤷ Try for Free
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering balversa around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Chile | 2016002382 | Derivados de quinoxalina útiles como moduladores de fgfr quinasa | ⤷ Try for Free |
Philippines | 12017501421 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N`-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE | ⤷ Try for Free |
Taiwan | I798199 | ⤷ Try for Free | |
South Korea | 102469506 | ⤷ Try for Free | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Market Dynamics and Financial Trajectory for BALVERSA (Erdafitinib)
More… ↓